Tests hyperbaric oxygen therapy for long-lasting depression after stroke
Tests a pressurized oxygen treatment in people with lasting depression after stroke.
Plain-language title generated from the registry record
Registry title: Hyperbaric Oxygen Therapy for Persistent Post Stroke Depression
Key facts
- Where
- Zrifin, IsraelSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 85 years old?
Source: NCT07423273, who can take part
Where in Israel
- The Sagol Center for Hyperbaric Medicine and Research Shamir Medical Center (Assaf Harofeh)Zrifin, IsraelTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Assaf-Harofeh Medical Center
- Trial code
- NCT07423273
- Record updated
- 17 April 2026
- Original description
The study evaluates the effect of HBOT on depression in patients suffering from persistent symptoms of post stroke depression (PSD) in an double blind sham control study.Read full original descriptionShow less
Hyperbaric Oxygen Therapy for Persistent Post Stroke Depression: A Prospective, Randomized, Double Blind Study
The study evaluates the effect of HBOT on depression in patients suffering from persistent symptoms of post stroke depression (PSD) in an double blind sham control study.
Inclusion: Age between 50 -85; Suffered an ischemic stroke 6 months to 7 years prior to their inclusion; Treated or being treated by antidepressants for at least 3 months; Diagnosis of PSD based on HDRS-17 score of 17 and above; Stable psychological and pharmacological treatment for more than three months prior to inclusion; Subject willing and able to read, understand and sign an informed consent.
Exclusion: Diagnosis of a psychiatric disorder prior to the recent stroke including: major depression, schizophrenia or bipolar disease; HBOT for any reason prior to study enrolment; History of Deep brain stimulation (DBS); History of traumatic brain injury, brain tumors, brain surgery, chronic subdural haemorrhages, Epilepsy; Active malignancy; History of other neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Lewy body dementia (LBD), Frontotemporal dementia (FTD), Multiple sclerosis (MS), Amyotrophic lateral sclerosis (ALS), Creutzfeld Jacob disease (CJD), Multisystem atrophy (MSA), Pseudobulbar palsy (PSP), Corticobasal degeneration (CBD), Wernicke Korsakoff syndrome; Renal or liver insufficiency, electrolyte imbalances; Chronic heart failure with ejection fraction of 30 or less; Inability to attend scheduled clinic visits and/or comply with the study protocol; Diagnosis of aphasia or major cognitive decline; Substance use at baseline; Serious suicidal ideation; Chest pathology incompatible with pressure changes (including active asthma or COPD); Ear or Sinus pathology incompatible with pressure changes (above 3 otolaryngologist visits a year); An inability to perform an awake brain MRI; No evidence of vascular related lesions in the brain MRI; Active smoking; Participation in another study.